Gilead to acquire Ouro Medicines for $1.675 billion upfront, autoimmune T-cell engager

Gilead agreed to acquire privately held Ouro Medicines, which is developing T-cell engagers for autoimmune diseases. The upfront cash payment is $1.675 billion, with up to $500 million more in milestones. The lead asset, gamgertamig (OM336), is a BCMAxCD3 T-cell engager that is expected to enter registrational studies in 2027.

• Upfront cash $1.675 billion, subject to customary adjustments
• Up to $500 million in contingent milestone payments
• Lead asset gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager
• Registrational studies expected to start in 2027